Epidermolysis Bullosa: Innovative Treatment with Stem Cells, a Systematic Review

Author:

Zurita Delgado KatherineORCID,Recalde Navarrete RicardoORCID

Abstract

Introduction: epidermolysis bullosa is a set of genetic disorders that originate from modifications in certain skin proteins that alter the union and structure of the dermis and epidermis. Clinically, it manifests itself through blisters. However, these lesions can spread to other areas. areas of the body, thus causing the appearance of chronic wounds. The conventional treatment of Epidermolysis Bullosa has not been shown to improve the long-term quality of life of those who suffer from it, which is why researchers propose new therapies that allow improvements in the quality of life of patients, being one of the most promising, the use of stem cells. Methods: randomized clinical trials were selected that evaluated the efficacy and safety of stem cell treatment in patients with Epidermolysis bullosa compared to usual therapy and its cost-effectiveness. Results: based on the selected articles, several variables were measured. Four articles demonstrated the effectiveness of stem cell treatment compared to conventional treatment; two articles measured the economic considerations and access to this new treatment; four articles compared the benefits and disadvantages of using stem cells in patients with Epidermolysis bullosa; and finally, five articles demonstrated the impact that stem cells have in improving the quality of life of patients with Epidermolysis bullosa who undergo this type of therapy. Conclusions: at a global level, the effectiveness of the use of stem cells opens a promising research perspective that seeks to benefit the most vulnerable population affected by this disease, since it plays a key role in the significant reduction of blistering lesions, this represents a positive advance. in the management of the disease, as well as the improvement in its biological, psychological and social sphere, allowing an early introduction to daily activities, generating significant savings of resources for caregivers and for the State. Because, in Latin America, to date there is little research in this area, it should be considered a very promising line of research in the field of Dermatology. Similar situation in the case of Ecuador, where since there are no statistics on patients with this disease, nor data that contribute to the treatment of this vulnerable group, these investigations will provide a solid basis for researchers to adopt this new therapy

Publisher

Salud, Ciencia y Tecnologia

Reference25 articles.

1. 1. Isis Elianis Rubio Rojas D, Mariana López Moro D. REVISION BIBLIOGRAFICA TITULO: LAS ENFERMEDADES RARAS. EPIDERMÓLISIS BULLOSA [Internet]. 2023. Available from: https://genmed.sld.cu/index.php/gemed23/2023/paper/view/36

2. 2. Hon KL, Chu S, Leung AKC. Epidermolysis Bullosa: Pediatric Perspectives. Curr Pediatr Rev [Internet]. 2022 Jun 14 [cited 2024 Mar 22];18(3):182–190. Available from: https://pubmed.ncbi.nlm.nih.gov/34036913/

3. 3. Amanda Vázquez Núñez M, Eloy Santiesteban Alejo R, Inés Ferrer Mora Y. Epidermólisis ampollosa o bullosa congénita. Actualización clínica Congenital Bullous Epidermolysis. Clinical Update. 2021 [cited 2023 Dec 27]; Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S2221-24342021000100074

4. 4. Hou PC, Wang HT, Abhee S, Tu WT, McGrath JA, Hsu CK. Investigational Treatments for Epidermolysis Bullosa. Am J Clin Dermatol [Internet]. 2021 Nov 22 [cited 2024 Mar 22];22(6):801–817. Available from: https://pubmed.ncbi.nlm.nih.gov/34292508/

5. 5. Bardhan A, Bruckner-Tuderman L, Chapple ILC, Fine JD, Harper N, Has C, Magin TM, Marinkovich MP, Marshall JF, McGrath JA, Mellerio JE, Polson R, Heagerty AH. Epidermolysis bullosa. Nat Rev Dis Primers [Internet]. 2020 Sep 24 [cited 2024 Mar 22];6(1):78. Available from: https://pubmed.ncbi.nlm.nih.gov/32973163/

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3